Free Trial

Renaissance Technologies LLC Sells 5,900 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories logo with Medical background

Renaissance Technologies LLC trimmed its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 44.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,500 shares of the medical instruments supplier's stock after selling 5,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.14% of Mesa Laboratories worth $989,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MLAB. Amundi lifted its holdings in shares of Mesa Laboratories by 81.6% in the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after buying an additional 297 shares in the last quarter. Resona Asset Management Co. Ltd. bought a new position in shares of Mesa Laboratories during the 4th quarter valued at about $92,000. KLP Kapitalforvaltning AS purchased a new position in shares of Mesa Laboratories during the fourth quarter valued at about $132,000. Berry Wealth Group LP increased its holdings in shares of Mesa Laboratories by 5.3% in the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock worth $219,000 after purchasing an additional 83 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its position in shares of Mesa Laboratories by 4.3% in the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock worth $231,000 after buying an additional 73 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Price Performance

NASDAQ MLAB traded up $0.11 during trading on Tuesday, hitting $118.64. 38,233 shares of the stock traded hands, compared to its average volume of 39,235. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $155.12. The firm has a 50-day simple moving average of $120.05 and a 200-day simple moving average of $126.52. The company has a market capitalization of $644.71 million, a P/E ratio of -2.56 and a beta of 0.97.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. As a group, analysts predict that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be paid a $0.16 dividend. The ex-dividend date is Friday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.54%. Mesa Laboratories's payout ratio is currently -1.38%.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the sale, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at $5,369,887.67. The trade was a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.40% of the company's stock.

About Mesa Laboratories

(Free Report)

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.

Featured Stories

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Should You Invest $1,000 in Mesa Laboratories Right Now?

Before you consider Mesa Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.

While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines